Summary of Rigel Pharmaceuticals Q1 2026 Earnings Call

1Key Financial Results and Metrics:

Net Product Sales: $54.9 million, a 26% increase year-over-year from Q1 2025.

TAVALISSE: $37.3 million (31% growth)

GAVRETO: $9.6 million (7% growth)

REZLIDHIA: $8 million (31% growth)

Total Revenue: $58.8 million, including $3.9 million from collaborations.

Net Income: $8.7 million, down from $11.4 million in Q1 2025.

Cash Position: $146.7 million, down from $155 million at the end of 2025.

Cost of Sales: Approximately $4.6 million; total expenses increased to $46.9 million from $40.6 million in the prior year.

2Strategic Updates and Business Highlights:

Rigel is focused on expanding its product portfolio and advancing its clinical pipeline. The company now has three commercial products and is pursuing in-licensing opportunities for late-stage assets.

The R289 program for lower-risk MDS is progressing, with data expected by year-end 2026.

Rigel's growth strategy is built on four pillars: commercial execution, pipeline expansion, clinical development, and financial discipline.

The company has successfully integrated new products and is exploring larger-scale in-licensing opportunities.

3Forward Guidance and Outlook:

Rigel maintains its 2026 revenue guidance of $275 million to $290 million, with net product sales projected between $255 million and $265 million.

The company anticipates achieving net income profitability for the full year and plans to continue funding clinical development opportunities.

4Bad News, Challenges, or Points of Concern:

The collaboration with Lilly for the RIPK1 inhibitor (ocodusertib) will terminate, effective June 15, 2026. This may impact Rigel's strategic focus as it regains rights to the program.

The plateauing revenue for GAVRETO raises concerns about market competition and the need for increased awareness among prescribers.

Increased costs in R&D and commercial expenses may pressure profitability despite revenue growth.

5Notable Q&A Insights:

Management acknowledged the challenges in growing REZLIDHIA's adoption in community settings, emphasizing the need for effective communication of its benefits in the post-venetoclax treatment landscape.

Questions about R289 highlighted the importance of safety and efficacy benchmarks for potential FDA registration studies, with management expressing optimism based on preliminary data.

The sales team noted that community physicians may be hesitant to switch from established treatments, indicating a need for ongoing education and support to drive adoption of Rigel's products. Overall, Rigel Pharmaceuticals reported solid growth in Q1 2026, with a focus on expanding its product offerings and advancing its clinical pipeline, while also facing challenges related to market competition and collaboration terminations.